Summary:
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Qualified Participants Must:
At least 18 years old or older
Being Diagnosed with Plantar Fascia fibromatosis
Qualified Participants May Receive:
Compensation for time and travel